The portable, patient-administered neuromodulation device utilizes a mild electrical current. It stimulates targeted brain areas resulting in a significant improvement in depressive symptoms.
“We are thrilled to receive this breakthrough designation from the FDA,” said Tuomas Neuvonen, Sooma CEO. “This designation recognizes that our device is a perfect solution, enabling a fast, effective and affordable treatment on a greater scale.
Neuvonen added that the company aims to make the treatment accessible to patients in U.S. “as quickly as possible.”
Sooma said its depression therapy offers a flexible treatment option with accessibility and affordability. It could benefit those underserved by medication or with limited access to …